Milestones
The pipeline list has been updated to 114 targets; every validated target is backed by experimental records from antigen preparation, antibody screening or functional validation.
SanjingBio has now validated more than 100 drug targets, while its active pipeline list has grown to 114 targets across oncology, autoimmune disease and metabolism.
Every validated target is supported by experimental records from antigen preparation, antibody screening or functional validation, including challenging classes such as multi-pass membrane proteins. The public pipeline records the latest completed stage for each target.
Core instruments now number 13. The 300 kV cryo-EM will be used for epitope analysis and complex-structure confirmation, supporting antigen design and antibody screening on membrane proteins and other hard targets.
Jul 21, 2026
Deliveries span mammalian, insect, yeast, E. coli and cell-free systems, with hard targets such as multi-pass membrane proteins taking a growing share.
Jun 12, 2026
New SKUs concentrate on solid tumours and autoimmune disease; every in-stock item ships immediately with purity data and ELISA binding validation.
May 8, 2026
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
